Vertex snaps up Cambridge diabetes startup Semma for $950M

Vertex Pharmaceuticals has struck a deal to acquire local diabetes-focused startup Semma Therapeutics, marking another substantial pivot for the company as CEO Jeff Leiden’s tenure comes to a close.